"The Company’s cash position of $23.6 million at 31 December 2020 combined with significant accrued research and development rebate credits means Recce Pharmaceuticals is sufficiently funded to execute its development milestones through the 2021 financial year. " interim report 31 dec 2020
"Recce Clinical Pipeline Update " says "Full data" end Q4, 2021 and 2022 and mid-2022 for results add in the wild card Covid data anticipated Q4 2021giving several near term re-ratings.
In for the results pipeline for me . I may need to change my user name to BIOTECH tragic The little dip today made me jump.
Have a great day all
RCE Price at posting:
$1.06 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
The little dip today made me jump.
(20min delay)